Comparative in vitro activity of voriconazole and itraconazole against fluconazole-susceptible and fluconazole-resistant clinical isolates of Candida species from Spain

被引：37

作者：

Cuenca-Estrella, M ^{[1
]}

Díaz-Guerra, TM ^{[1
]}

Mellado, E ^{[1
]}

Monzón, A ^{[1
]}

Rodríguez-Tudela, JL ^{[1
]}

机构：

[1] Inst Salud Carlos III, Ctr nacl Microbiol, Unidad Micol, E-28220 Madrid, Spain

来源：

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES | 1999年 / 18卷 / 06期

关键词：

D O I：

10.1007/s100960050313

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

The in vitro activity of voriconazole was compared with that of itraconazole against 299 fluconazole-susceptible (MIC less than or equal to 8 mu g/ml) and 130 fluconazole-resistant (MIC greater than or equal to 16 mu g/ml) clinical isolates of Candida spp. An adaptation of the National Committee for Clinical Laboratory Standards reference method was employed for determination of MICs. Voriconazole showed more potent activity than either fluconazole and itraconazole, even against some Candida albicans, Candida glabrata, and Candida krusei isolates resistant to fluconazole, However, for fluconazole-resistant isolates, the MICs of itraconazole and voriconazole were proportionally higher than for fluconazole-susceptible isolates. These data may indicate cross-resistance.

引用

页码：432 / 435

页数：4

共 15 条

[1] In vitro studies of two triazole antifungal agents (Voriconazole [UK-109,496] and fluconazole) against Candida species [J].

Barry, AL ;

Brown, SD .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (08) :1948-1949

[2] Voriconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistant Candida species [J].

Belanger, P ;

Nast, CC ;

Fratti, R ;

Sanati, H ;

Ghannoum, M .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (08) :1840-1842

[3] Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery [J].

Caillot, D ;

Casasnovas, O ;

Bernard, A ;

Couaillier, JF ;

Durand, C ;

Cuisenier, B ;

Solary, E ;

Piard, F ;

Petrella, T ;

Bonnin, A ;

Couillault, G ;

Dumas, M ;

Guy, H .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (01) :139-147

[4] International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections [J].

Edwards, JE ;

Bodey, GP ;

Bowden, RA ;

Buchner, T ;

dePauw, BE ;

Filler, SG ;

Ghannoum, MA ;

Glauser, M ;

Herbrecht, R ;

Kauffman, CA ;

Kohno, S ;

Martino, P ;

Meunier, F ;

Mori, T ;

Pfaller, MA ;

Rex, JH ;

Rogers, TR ;

Rubin, RH ;

Solomkin, J ;

Viscoli, C ;

Walsh, TJ ;

White, M .

CLINICAL INFECTIOUS DISEASES, 1997, 25 (01) :43-59

[5] In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens [J].

Espinel-Ingroff, A .

JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (01) :198-202

[6]

Hegener P, 1998, AIDS, V12, P2227

[7] In vitro activity of voriconazole against Candida species [J].

Kauffman, CA ;

Zarins, LT .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1998, 31 (01) :297-300

[8] In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp. [J].

Marco, F ;

Pfaller, MA ;

Messer, S ;

Jones, RN .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (01) :161-163

[9] Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs [J].

Martin, MV ;

Yates, J ;

Hitchcock, CA .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (01) :13-16

[10]

NATIONAL COMMITTEE FOR CLINICAL LABORATORY STANDARDS-NCCLS, 1997, M27A NCCLS

← 1 2 →